keyword
MENU ▼
Read by QxMD icon Read
search

methylphenidate adhd

keyword
https://www.readbyqxmd.com/read/29786810/-epilepsy-and-comorbid-neurodevelopmental-disorders
#1
Viviann Nordin, Ingrid B Olsson, Torbjörn Tomson
In children and adults with epilepsy, it is important to be aware of and diagnose common comorbidities that may have a large impact on quality of life. Comorbid neurodevelopmental disorders include intellectual disability, autism, and attention deficit hyperactivity disorder (ADHD). Depression and anxiety are common findings, and also the risk of psychosis is increased. The medication used to treat these comorbidities is found to be effective with little risks of seizure exacerbation, i.e. medication with methylphenidate, selective serotonin reuptake inhibitors (SSRIs) and second generation neuroleptics...
May 22, 2018: Läkartidningen
https://www.readbyqxmd.com/read/29784754/pediatric-adhd-medication-exposures-reported-to-us-poison-control-centers
#2
Samantha A King, Marcel J Casavant, Henry A Spiller, Nichole L Hodges, Thitphalak Chounthirath, Gary A Smith
: media-1vid110.1542/5754332180001PEDS-VA_2017-3872 Video Abstract OBJECTIVES: To describe the characteristics and trends of exposures to attention-deficit/hyperactivity disorder (ADHD) medications among individuals 0 to 19 years old reported to US poison control centers. METHODS: National Poison Data System data from 2000 through 2014 were retrospectively analyzed to examine pediatric ADHD medication exposures. RESULTS: From 2000 through 2014, there were 156 365 exposures reported to US poison control centers related to ADHD medications...
May 21, 2018: Pediatrics
https://www.readbyqxmd.com/read/29777288/time-shifting-effects-of-methylphenidate-on-daily-rhythms-in-the-diurnal-rodent-arvicanthis-ansorgei
#3
Jorge Mendoza, Hester C van Diepen, Rob Rodrigues Pereira, Johanna H Meijer
People suffering of attention-deficit/hyperactivity disorder (ADHD) and treated with the psychostimulant methylphenidate (MPH) show sleep-wake cycle and daily rhythm alterations despite the beneficial effects of MPH on behavioral symptoms (i.e., hyperactivity, attention). In nocturnal rodents (i.e., mice), chronic exposure to MPH alters the neural activity of the circadian clock in the suprachiasmatic nucleus (SCN), behavioral rhythms, and the sleep-wake cycle. Here, we studied the effects of MPH on daily rhythms of behavior and body temperature of the diurnal rodent Arvicanthis ansorgei...
May 18, 2018: Psychopharmacology
https://www.readbyqxmd.com/read/29768038/use-and-characteristics-of-antipsychotic-methylphenidate-combination-therapy-in-children-and-adolescents-with-a-diagnosis-of-attention-deficit-hyperactivity-disorder
#4
Oliver Scholle, Tobias Banaschewski, Dirk Enders, Edeltraut Garbe, Oliver Riedel
OBJECTIVE: Children and adolescents with attention-deficit/hyperactivity disorder (ADHD) frequently have comorbidities that are potential indications for antipsychotics (APs). Some studies have suggested that the combined use of methylphenidate (MPH) and APs is increasing in this population group. Longitudinal analyses and in-depth investigations on the substance level are lacking. This study aimed to estimate the cumulative proportion of concomitant AP/MPH use in children and adolescents with ADHD over a follow-up of up to 9 years and to describe patient characteristics stratified by specific AP drug...
May 16, 2018: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/29768018/psychostimulants-influence-on-body-mass-index-and-height-in-a-pediatric-population-with-attention-deficit-hyperactivity-disorder
#5
Yvette E Lentferink, Ewoudt M W van de Garde, Catherijne A J Knibbe, Marja M J van der Vorst
OBJECTIVES: Attention-deficit/hyperactivity disorder (ADHD) is often treated with psychostimulants. Psychostimulants' adverse effects on body mass index standard deviation score (BMI-sds) and height in children/adolescents with ADHD have been reported. However, literature is inconsistent, and it is unclear whether the observed effects are dosage- and/or BMI-dependent. Therefore, the aim of this retrospective observational study is to evaluate the influence of psychostimulants on BMI-sds and height-sds in a pediatric cohort with ADHD from an outpatient clinic, and to study the correlation between psychostimulant dosage and BMI-sds and height-sds change...
May 16, 2018: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/29765401/mixed-effects-modeling-of-neurofeedback-self-regulation-performance-moderators-for-learning-in-children-with-adhd
#6
Agnieszka Zuberer, Franziska Minder, Daniel Brandeis, Renate Drechsler
Introduction: Neurofeedback (NF) has gained increasing popularity as a training method for children and adults with attention deficit hyperactivity disorder (ADHD). However, it is unclear to what extent children learn to regulate their brain activity and in what way NF learning may be affected by subject- and treatment-related factors. Methods: In total, 48 subjects with ADHD (age 8.5-16.5 years; 16 subjects on methylphenidate (MPH)) underwent 15 double training sessions of NF in either a clinical or a school setting...
2018: Neural Plasticity
https://www.readbyqxmd.com/read/29765219/estimated-prevalence-and-incidence-of-diagnosed-adhd-and-health-care-utilization-in-adults-in-sweden-a-longitudinal-population-based-register-study
#7
Maria Polyzoi, Ewa Ahnemark, Emma Medin, Ylva Ginsberg
Background: Although the worldwide prevalence of attention-deficit/hyperactivity disorder (ADHD) in adults is estimated to be between 2% and 5%, it is considered to be underdiagnosed. This register study explored the prevalence of diagnosed ADHD and incidence of newly diagnosed ADHD in Swedish adults over time, and assessed comorbidities and pharmacologic treatment. Methods: National Patient Register data were used to estimate the overall prevalence of adults (≥18 years) with a registered ADHD diagnosis from 2006 to 2011, and the incidence of newly registered diagnoses from 2007 to 2011...
2018: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29756071/improving-the-quality-of-physical-health-monitoring-in-camhs-for-children-and-adolescents-prescribed-medication-for-adhd
#8
Cristal Oxley, Omer S Moghraby, Rani Samuel, Dan W Joyce
Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder characterised by a persistent, pervasive pattern of inattention, impulsivity and hyperactivity. Stimulant medication such as methylphenidate has an established evidence base in the treatment of children and adolescents with ADHD. However, it is also associated with a risk of side effects which may include decreased appetite, increased blood pressure and possible reduced growth. Monitoring physical health in children and adolescents prescribed medication for ADHD is a key clinical responsibility and includes a number of parameters as outlined in the National Institute for Health and Care Excellence Guidelines...
2018: BMJ Open Quality
https://www.readbyqxmd.com/read/29751051/neurocognitive-effects-of-methylphenidate-in-adults-with-attention-deficit-hyperactivity-disorder-a-meta-analysis
#9
REVIEW
Michelle A Pievsky, Robert E McGrath
PIEVSKY, M. A., and R. E. McGrath. Neurocognitive effects of methylphenidate in adults with attention-deficit/hyperactivity disorder: A meta-analysis…NEUROSCI BIOBEHAV REV 81(1) XXX-XXX, 2017.- This meta-analysis summarized 21 double-blind randomized controlled trials with a mean study duration of 18 days comparing the neurocognitive functioning of adults with attention-deficit/hyperactivity disorder (ADHD) on methylphenidate vs placebo. Effect sizes were weighted using a random-effects model. Scores on neurocognitive measures and tests of driving ability were on average higher on methylphenidate than on placebo, g = ...
May 8, 2018: Neuroscience and Biobehavioral Reviews
https://www.readbyqxmd.com/read/29750737/inter-and-intraindividual-variation-of-methylphenidate-concentrations-in-serum-and-saliva-of-patients-with-attention-deficit-hyperactivity-disorder
#10
Joshua Preiskorn, Sophie Studer, Reinhold Rauh, Richard Lukačin, Christoph Geffert, Christian Fleischhaker, Hans-Willi Clement, Eberhard Schulz, Monica Biscaldi
BackgroundTherapeutic drug monitoring (TDM) is becoming increasingly important in psychiatric therapy; especially in children. However, for several reasons, it cannot yet be implemented as a daily routine in clinical or outpatient settings. To evaluate new, non-invasive procedures; blood and saliva (oral fluid) samples were collected from patients with attention-deficit/hyperactivity disorder (ADHD) who were also being administered methylphenidate (MPH). The study's main purposes were to correlate MPH concentrations in serum and saliva between subjects; and to analyze intraindividual variation of serum concentration...
May 3, 2018: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/29744873/methylphenidate-for-attention-deficit-hyperactivity-disorder-adhd-in-children-and-adolescents-assessment-of-adverse-events-in-non-randomised-studies
#11
REVIEW
Ole Jakob Storebø, Nadia Pedersen, Erica Ramstad, Maja Lærke Kielsholm, Signe Sofie Nielsen, Helle B Krogh, Carlos R Moreira-Maia, Frederik L Magnusson, Mathilde Holmskov, Trine Gerner, Maria Skoog, Susanne Rosendal, Camilla Groth, Donna Gillies, Kirsten Buch Rasmussen, Dorothy Gauci, Morris Zwi, Richard Kirubakaran, Sasja J Håkonsen, Lise Aagaard, Erik Simonsen, Christian Gluud
BACKGROUND: Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in childhood. The psychostimulant methylphenidate is the most frequently used medication to treat it. Several studies have investigated the benefits of methylphenidate, showing possible favourable effects on ADHD symptoms, but the true magnitude of the effect is unknown. Concerning adverse events associated with the treatment, our systematic review of randomised clinical trials (RCTs) demonstrated no increase in serious adverse events, but a high proportion of participants suffered a range of non-serious adverse events...
May 9, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29739137/methylphenidate-induced-lip-and-tongue-biting
#12
Cem Gokcen, Mehmet Karadag, Ihsan Aksoy
Attention deficit hyperactivity disorder (ADHD) is a life-long neurodevelopmental disorder and treatment depends on pharmacotherapy because of its biological origin. Stimulant drugs are the most commonly used treatment for ADHD and they have various side effects. Herein, we report a case who bit off the tip of her tongue with Osmotic Release Oral System methylphenidate (OROS MPH) 36 mg/day, bit the tip of her lower lip with immediate release (IR) MPH 10 mg/day and lateral part of her tongue with IR MPH 20 mg/day...
May 31, 2018: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29733106/how-do-stimulant-treatments-for-adhd-work-evidence-for-mediation-by-improved-cognition
#13
Larry W Hawk, Whitney D Fosco, Craig R Colder, James G Waxmonsky, William E Pelham, Keri S Rosch
BACKGROUND: Stimulant medications such as methylphenidate (MPH) are the frontline treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). Despite their well-documented efficacy, the mechanisms by which stimulants improve clinical outcomes are not clear. The current study evaluated whether MPH effects on classroom behavior were mediated by improved cognitive functioning. METHODS: Children with ADHD (n = 82; 9-12 years old) participated in a week-long summer research camp, consisting of cognitive testing, classroom periods, and recreational activities...
May 7, 2018: Journal of Child Psychology and Psychiatry, and Allied Disciplines
https://www.readbyqxmd.com/read/29716850/methylphenidate-induced-hepatotoxicity-in-rats-and-its-reduction-by-buspirone
#14
Nausheen Alam, Rahila Ikram
Methylphenidate is commonly use for the treatment of attention deficit hyperactivity disorder (ADHD), but its long term use was found to produce hepatic necrosis in mice. Purpose of this study was to investigate that co-administration of buspirone (drug which attenuates methylphenidate induced sensitization) may attenuate methylphenidate-induced hepatotoxic effects and to determine the effect of challenge dose of haloperidol (D2 antagonist that blocks the effects of methylphenidate in case of intoxication) on SGPT and SGOT levels in methylphenidate treated rats...
May 2018: Pakistan Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/29708762/improvements-in-irritability-with-open-label-methylphenidate-treatment-in-youth-with-comorbid-attention-deficit-hyperactivity-disorder-and-disruptive-mood-dysregulation-disorder
#15
Drew E Winters, Sadaaki Fukui, Ellen Leibenluft, Leslie A Hulvershorn
OBJECTIVE: The purpose of this open-label study was to examine the effects of long-acting methylphenidate (MPH) treatment on irritability and related emotional symptoms associated with disruptive mood dysregulation disorder (DMDD) in youth with comorbid attention-deficit/hyperactivity disorder (ADHD). METHODS: The sample included 22 medication-free male and female subjects (ages 9-15) who met criteria for both DMDD and ADHD. Participants underwent a 4-week trial of long-acting MPH treatment (Concerta® ), with weekly dosing increases until a therapeutic dose was reached...
April 30, 2018: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/29703430/relative-bioavailability-of-methylphenidate-extended-release-chewable-tablets-chewed-versus-swallowed-whole
#16
Richat Abbas, Ann C Childress, Praneeta Nagraj, Richard Rolke, Sally A Berry, Donna R Palumbo
PURPOSE: Methylphenidate hydrochloride extended-release chewable tablet (MPH ERCT) is approved for treatment of attention deficit hyperactivity disorder in patients aged 6 years and older. This article evaluates the pharmacokinetic parameters and relative bioavailability of MPH ERCT when chewed versus swallowed whole. METHODS: In this open-label, single-dose, 3-period, 3-treatment crossover study, 12 healthy adult volunteers were randomly assigned to treatment sequence...
April 24, 2018: Clinical Therapeutics
https://www.readbyqxmd.com/read/29693461/an-update-on-pharmacotherapy-of-autism-spectrum-disorder-in-children-and-adolescents
#17
Ritu Goel, Ji Su Hong, Robert L Findling, Na Young Ji
To date, no medication is proven to be effective in treating core symptoms of autism spectrum disorder (ASD). Psychotropic medications are widely used to target emotional and behavioural symptoms in ASD. This article reviewed evidence for pharmacotherapy, novel therapeutic agents, and Complementary and Alternative Medicine (CAM) in children and adolescents with ASD. Currently, only risperidone and aripiprazole have been approved by the US Food and Drug Administration (FDA) for treatment of irritability associated with ASD in children and adolescents...
April 25, 2018: International Review of Psychiatry
https://www.readbyqxmd.com/read/29684537/genetic-imaging-study-with-tc-99m-trodat-1-spect-in-adolescents-with-adhd-using-oros-methylphenidate
#18
Aynur Pekcanlar Akay, Gamze Çapa Kaya, Samet Kose, Çiğdem Eresen Yazıcıoğlu, Handan Özek Erkuran, Sevay Alşen Güney, Kaya Oğuz, Duygu Keskin, Burak Baykara, Neslihan İnal Emiroğlu, Mine Şencan Eren, Sefa Kızıldağ, Türkan Ertay, Dua Özsoylu, Süha Miral, Hatice Durak, Ali Saffet Gönül, Luis Augusto Rohde
AIM: To examine theeffects on the brain of 2-month treatment withamethylphenidate extended-release formulation (OROS-MPH) using [Tc-99m ] TRODAT-1SPECT in a sample of treatment-naïve adolescents with Attention Deficit/Hyperactivity Disorder (ADHD). In addition, to assess whether risk alleles (homozygosity for 10-repeat allele at the DAT1 gene were associated with alterations in striatal DAT availability. METHODS: Twenty adolescents with ADHD underwent brain single-photon emission computed tomography (SPECT) scans with [Tc-99m ] TRODAT-1 at baseline and two months after starting OROS-MPH treatment with dosages up to 1 mg/kg/day...
April 20, 2018: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/29670821/amphetamine-but-not-methylphenidate-increases-ethanol-intake-in-adolescent-male-but-not-in-female-rats
#19
Paul Ruiz, Aldo Calliari, Patricia Genovese, Cecilia Scorza, Ricardo Marcos Pautassi
Introduction: There has been an increasing interest in analyzing the interactions between stimulants and ethanol during childhood and adolescence. Stimulants are used to treat attention-deficit hyperactivity disorder (ADHD) in these developmental stages, during which ethanol initiation and escalation often occur. Methods: This study assessed the effects of repeated d-amphetamine (AMPH) or methylphenidate (MPH) treatment during adolescence [male and female Wistar rats, between postnatal day (PD) 28 to PD34, approximately] on the initiation of ethanol intake during a later section of adolescence (PD35 to PD40)...
April 2018: Brain and Behavior
https://www.readbyqxmd.com/read/29662527/stimulant-withdrawal-in-a-child-with-autism-spectrum-disorder-and-adhd-a-case-report
#20
Aneta Krakowski, Abel Ickowicz
Objective: To consider whether the concepts of tolerance and withdrawal to stimulant medications apply to a preadolescent female, affected by autism spectrum disorder (ASD) and treated for associated attention-deficit/hyperactivity disorder (ADHD). Methods: We describe the case history and review scientific English language literature pertaining to acute withdrawal effects associated with methylphenidate and amphetamine derivatives in children. Results: An 11-year-old female with ASD and ADHD referred to our clinic experienced vomiting, headaches, and light sensitivity following abrupt discontinuation of methylphenidate; she subsequently presented with migraines and marked malaise immediately after a dose reduction in lisdexamfetamine...
April 2018: Journal of the Canadian Academy of Child and Adolescent Psychiatry
keyword
keyword
116871
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"